share_log

Some Investors May Be Willing To Look Past Renhe PharmacyLtd's (SZSE:000650) Soft Earnings

Some Investors May Be Willing To Look Past Renhe PharmacyLtd's (SZSE:000650) Soft Earnings

一些投資者可能願意忽略仁和藥業股份有限公司(SZSE:000650)的低收益。
Simply Wall St ·  11/05 14:27

The most recent earnings report from Renhe Pharmacy Co.,Ltd (SZSE:000650) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income statement.

仁和藥業股份有限公司(SZSE:000650)最新的收益報告令股東失望。儘管利潤數據較弱,我們的分析師對財務報表的總體質量持樂觀態度。

big
SZSE:000650 Earnings and Revenue History November 5th 2024
SZSE:000650盈利和營收歷史2024年11月5日

The Impact Of Unusual Items On Profit

除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。

To properly understand Renhe PharmacyLtd's profit results, we need to consider the CN¥130m expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. If Renhe PharmacyLtd doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

爲了正確認識仁和藥業有限公司的盈利結果,我們需要考慮歸因於飛凡項目的13000萬人民幣開支。雖然由於飛凡項目導致的扣除在第一時間令人失望,但也有一線希望。我們查看了成千上萬家上市公司,發現飛凡項目很常見且通常是一次性的。鑑於這些項被認爲是異常的,這並不奇怪。如果仁和藥業有限公司沒有再出現這些異常費用,其他條件不變的情況下,我們預計其利潤在未來一年內將會增加。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Renhe PharmacyLtd.

備註:我們始終建議投資者檢查資產負債表的實力。點擊這裏查閱我們對仁和藥業有限公司資產負債表的分析。

Our Take On Renhe PharmacyLtd's Profit Performance

我們對仁和藥業有限公司的盈利表現看法

Unusual items (expenses) detracted from Renhe PharmacyLtd's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Renhe PharmacyLtd's statutory profit actually understates its earnings potential! Unfortunately, though, its earnings per share actually fell back over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So while earnings quality is important, it's equally important to consider the risks facing Renhe PharmacyLtd at this point in time. For example, we've discovered 1 warning sign that you should run your eye over to get a better picture of Renhe PharmacyLtd.

飛凡項目(支出)削弱了仁和藥業過去一年的收益,但我們可能會在明年看到改善。根據這一觀察結果,我們認爲仁和藥業的法定利潤實際上低估了其盈利潛力!不幸的是,過去一年其每股收益實際上有所下降。當然,當涉及分析其盈利時,我們僅僅觸及了表面;人們還可以考慮利潤率、預測增長和投資回報率等其他因素。因此,儘管盈利質量很重要,但在此時考慮到仁和藥業面臨的風險同樣重要。例如,我們發現了1個警示信號,您應該睜大眼睛看一看,以更全面地了解仁和藥業。

Today we've zoomed in on a single data point to better understand the nature of Renhe PharmacyLtd's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

今天,我們放大了一個單一數據點,以更好地了解仁和藥業的利潤性質。但有許多其他方法可以幫助您了解一家公司。一些人認爲高股本收益率是一個質量優秀企業的好跡象。雖然可能需要您進行一些研究,但您可能會發現這些免費的公司集合中有許多股本回報率高的公司,或者具有重要內部持股的股票清單對您有所幫助。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論